Surrozen, Inc. (SRZN)

NASDAQ: SRZN · IEX Real-Time Price · USD
13.25
+0.33 (2.55%)
Mar 1, 2024, 4:00 PM EST - Market closed
2.55%
Market Cap 27.01M
Revenue (ttm) 12.50M
Net Income (ttm) -34.90M
Shares Out 2.04M
EPS (ttm) -17.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,355
Open 12.73
Previous Close 12.92
Day's Range 12.73 - 13.25
52-Week Range 4.50 - 17.25
Beta 0.39
Analysts n/a
Price Target n/a
Earnings Date Mar 20, 2024

About SRZN

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for th... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 74
Stock Exchange NASDAQ
Ticker Symbol SRZN
Full Company Profile

Financial Performance

Financial Statements

News

Surrozen Provides Corporate Update on Clinical Programs

Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic liv...

6 weeks ago - GlobeNewsWire

Surrozen Provides Third Quarter 2023 Financial Results

Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024

4 months ago - GlobeNewsWire

Surrozen Provides Second Quarter 2023 Financial Results

SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023

7 months ago - GlobeNewsWire

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and...

9 months ago - GlobeNewsWire

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023

10 months ago - GlobeNewsWire

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wn...

11 months ago - GlobeNewsWire

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023

1 year ago - GlobeNewsWire

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 finan...

1 year ago - GlobeNewsWire

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt...

1 year ago - GlobeNewsWire

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt...

1 year ago - GlobeNewsWire

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt...

1 year ago - GlobeNewsWire

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN) announced today that it has entered into a collaboration and license agreement with Boehringer Ingelheim to...

1 year ago - GlobeNewsWire

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Surrozen , Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair a...

1 year ago - GlobeNewsWire

Surrozen Reports Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt...

1 year ago - GlobeNewsWire

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively a...

1 year ago - GlobeNewsWire

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and ...

1 year ago - GlobeNewsWire

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively ac...

1 year ago - GlobeNewsWire

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Results highlight potential for novel approach to treating IBD with Wnt mimetic Results highlight potential for novel approach to treating IBD with Wnt mimetic

1 year ago - GlobeNewsWire

Surrozen Reports First Quarter 2022 Financial Results

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326...

1 year ago - GlobeNewsWire

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt ...

1 year ago - GlobeNewsWire

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Preclinical data suggest that SZN-413 can simultaneously address retinal non-perfusion and leakage in blood vessels in retinal vascular diseases Preclinical data suggest that SZN-413 can simultaneousl...

1 year ago - GlobeNewsWire

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022 On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326...

2 years ago - GlobeNewsWire

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022

2 years ago - GlobeNewsWire

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen to provide a business update including discussion of pipeline advancements Surrozen to provide a business update including discussion of pipeline advancements

2 years ago - GlobeNewsWire

Surrozen Reports Third Quarter 2021 Financial Results

Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022

2 years ago - GlobeNewsWire